| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Patent covers advanced signal processing for middle ear sensors, further advancing the Company's position in leveraging the ear for fully implanted hearing devices
White Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that it has received an Issue Notification from the European Patent Office and has been granted European Patent No. 4338791 which became effective September 17, 2025. The newly issued European patent strengthens Envoy Medical's global patent portfolio following recent issuances in the United States, Australia, and Hong Kong.
The title of the patent is "Implantable Cochlear System with Integrated Components and Lead Characterization" and relates to sophisticated systems and methods for compensating for variability in a middle ear sensor. Specifically, it covers the use of analog and digital signals from a middle ear sensor representing received stimulus signals. The digital filter can be adjusted to normalize the frequency response of the digitally filtered signals with respect to the stimulus signals.
Envoy Medical's fully implanted cochlear implant technology, including the investigational Acclaim® Cochlear Implant, is designed to eliminate the need for external microphones and wearable hardware, instead utilizing a sensor designed to leverage the natural ear. The company believes this technology represents a significant shift in the treatment paradigm for patients with severe to profound sensorineural hearing loss.
Posted In: COCH
